Terms and conditions
Legal and privacy notice
Cookie policy
GDPR statement
Webinar sign up
For further information
Transforming the world
of label material testing
for pharma
10 Mar 2022
Related news
10 Mar 2022
Live webinar: Streamlining
the qualification process for
label materials
10 Mar 2022
Avery Dennison launches
a new label testing service
Back to all news
Want to discuss how we can help you?
tm
© 2022 AD Procerta
Get in touch
News
Contact
Services
Our expertise
About
Download our brochure
There is no denying that pharmaceutical label materials can often be difficult
to navigate and manage. Determining the most suitable solution for products involves numerous factors and obstacles, from testing material applications to analyzing label performance in specific environments. As a result, pharmaceutical packaging engineers and brand owners are in dire need of a service that can assist them in streamlining this process as much as possible.
That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison,
a global leader in the packaging industry.
We talked with Jos van Noort, Principal Scientist Global Pharma Innovations and Benoît Jourde, Senior Manager New Growth Platforms Europe (both at Avery Dennison) who, along with many other experts, were instrumental in the development of AD Procerta. They explored topics such as the needs of the pharmaceutical industry and advised
on some factors to consider when selecting the right label material.
TM
There appear to be numerous parameters to consider when it comes to a label (not to mention the whole packaging).
Is it possible to pre select a label material for a specific application without conducting time-consuming and costly
in-production tests?
Jos: The typical method we’ve seen in the market is that the end-user or brand owner will collect all of the CTQs (as stated in the previous question), then select the test label material with the converter, and finally perform some testing. So, we created AD Procerta, a facility where a variety of label-specific tests can be performed with the guidance of an expert team to determine whether a label is suitable for a given application. Due to AD Procerta’s experience, your cycle time for introducing new material is reduced, and you’re assured of high-quality service because we’re working according to ISO 17025 standards.
Benoît: Essentially, we discovered that running labelling trials on manufacturing packaging lines can be difficult and costly (since production of the medicines must stop for the label the trial to take place). As you can imagine, it is difficult for packaging engineers to convince plant operations to allocate extra time for application trials within the plant.
In response to this challenge, we created laboratories that can mimic real life-cycles to speed up selection of label materials. Using this method, we can determine which label material has the greatest likelihood of success based upon effective tests in real-life scenarios that allow them to compare and contrast the options fairly. Therefore, to answer the question - yes, it is entirely possible to select the right material for the right application without spending a lot of time and money.
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
Jos: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
We'll also host two live webinars where we'll talk about the technical aspects of labeling materials for pharmaceutical packaging and how we can support you. These will take place on:
• March 31, 2022 15:00 CET
• April 12, 2022 11:00 CET
You can register for the webinars by clicking here.
download
full release
Want to discuss how we
can help you?
Get in touch
BACK TO
ALL NEWS
10 Mar 2022
Transforming the world
of label material testing
for pharma
10 Mar 2022
Webinar thumbnail, title TBC
Related news
tm
© 2022 AD Procerta
Terms and conditions
Legal and privacy notice
Cookie policy
GDPR statement
News
Contact
Services
Our expertise
About
That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
We talked with Jos van Noort, Principal Scientist Global Pharma Innovations and Benoît Jourde, Senior Manager New Growth Platforms Europe (both at Avery Dennison) who, along with many other experts, were instrumental in the development of
AD Procerta. They explored topics such as the needs of the pharmaceutical industry and advised on some factors to consider when selecting the right label material.
Labels are viewed as only a small component of packaging by many people. What is your perspective on this?
Benoît: The label is often the last phase of the packaging development, but it is an essential component since it will contain all the information necessary for patient safety. When it comes to printing information on products like medication, any application defects or lack of readability must really be avoided at all costs - the labels have to be highly robust. Putting it simply, you can’t use medication if its label doesn’t display all of the necessary information. But having said that,
I believe people are gradually recognizing the importance of labels in packaging and are no longer putting them off until the last moment, which is a positive and essential shift.
Jos: Physically, labels are a small component of a package, but they convey a great deal of information to its users. They contain crucial information such as usage and expiration dates, and each of these elements, as Benoît previously stated, are critical for
a pharmaceutical product and hence deserves a great deal of time, thought, and attention.
When a packaging engineer considers
a labelling solution for a product’s packaging, where should they begin?
Jos: If I were a packaging engineer, I’d start by gathering all of the CTQs (critical to quality) for a label. How is it applied? What is the nature of substrate? What are the conditions? What is the life-cycle of the material? These are only a few of the factors to consider. Once the packaging engineer has this information, they should contact a converter together with the label material manufacturer, such as Avery Dennison, for assistance in choosing the right label material for the application before getting started.
Benoît: I agree with Jos. It’s essentially
a combination of choosing the correct label material and the printing method that will be used to create the label. All of this will be influenced by the substrate’s nature, the application’s conditions, and so on.
The supply chain and volume will affect the printing technology, and the printing technology will impact the label material selection. There are therefore two main factors to consider here. The first factor concerns the label’s ability to adhere to and remain on the substrate. And the second, as previously said, is the printing of medical information that is crucial to the patient.
It is very important to make sure the label materials are compatible with the printing methods you choose; you can use either digital or conventional printing methods depending on your supply chain, the degree of flexibility required, the complexity level,
the volume, etc.
Thus, when it comes to packaging, you should consider the label material and printing technologies together instead of separately, and involve a label converter with the label material supplier, like Avery Dennison. That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
We talked with Jos van Noort, Principal Scientist Global Pharma Innovations and Benoît Jourde, Senior Manager New Growth Platforms Europe (both at Avery Dennison) who, along with many other experts, were instrumental in the development of
AD Procerta. They explored topics such as the needs of the pharmaceutical industry and advised on some factors to consider when selecting the right label material.
Labels are viewed as only a small component of packaging by many people. What is your perspective on this?
Benoît: The label is often the last phase of the packaging development, but it is an essential component since it will contain all the information necessary for patient safety. When it comes to printing information on products like medication, any application defects or lack of readability must really be avoided at all costs - the labels have to be highly robust. Putting it simply, you can’t use medication if its label doesn’t display all of the necessary information. But having said that,
I believe people are gradually recognizing the importance of labels in packaging and are no longer putting them off until the last moment, which is a positive and essential shift.
Jos: Physically, labels are a small component of a package, but they convey a great deal of information to its users. They contain crucial information such as usage and expiration dates, and each of these elements, as Benoît previously stated, are critical for
a pharmaceutical product and hence deserves a great deal of time, thought, and attention.
When a packaging engineer considers
a labelling solution for a product’s packaging, where should they begin?
Jos: If I were a packaging engineer, I’d start by gathering all of the CTQs (critical to quality) for a label. How is it applied? What is the nature of substrate? What are the conditions? What is the life-cycle of the material? These are only a few of the factors to consider. Once the packaging engineer has this information, they should contact a converter together with the label material manufacturer, such as Avery Dennison, for assistance in choosing the right label material for the application before getting started.
Benoît: I agree with Jos. It’s essentially
a combination of choosing the correct label material and the printing method that will be used to create the label. All of this will be influenced by the substrate’s nature, the application’s conditions, and so on.
The supply chain and volume will affect the printing technology, and the printing technology will impact the label material selection. There are therefore two main factors to consider here. The first factor concerns the label’s ability to adhere to and remain on the substrate. And the second, as previously said, is the printing of medical information that is crucial to the patient.
It is very important to make sure the label materials are compatible with the printing methods you choose; you can use either digital or conventional printing methods depending on your supply chain, the degree of flexibility required, the complexity level,
the volume, etc.
Thus, when it comes to packaging, you should consider the label material and printing technologies together instead of separately, and involve a label converter with the label material supplier, like Avery Dennison. That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
When a packaging engineer considers
a labelling solution for a product’s packaging, where should they begin?
That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
We talked with Jos van Noort, Principal Scientist Global Pharma Innovations and Benoît Jourde, Senior Manager New Growth Platforms Europe (both at Avery Dennison) who, along with many other experts, were instrumental in the development of
AD Procerta. They explored topics such as the needs of the pharmaceutical industry and advised on some factors to consider when selecting the right label material.
Labels are viewed as only a small component of packaging by many people. What is your perspective on this?
Benoît: The label is often the last phase of the packaging development, but it is an essential component since it will contain all the information necessary for patient safety. When it comes to printing information on products like medication, any application defects or lack of readability must really be avoided at all costs - the labels have to be highly robust. Putting it simply, you can’t use medication if its label doesn’t display all of the necessary information. But having said that,
I believe people are gradually recognizing the importance of labels in packaging and are no longer putting them off until the last moment, which is a positive and essential shift.
Jos: Physically, labels are a small component of a package, but they convey a great deal of information to its users. They contain crucial information such as usage and expiration dates, and each of these elements, as Benoît previously stated, are critical for
a pharmaceutical product and hence deserves a great deal of time, thought, and attention.
When a packaging engineer considers
a labelling solution for a product’s packaging, where should they begin?
Jos: If I were a packaging engineer, I’d start by gathering all of the CTQs (critical to quality) for a label. How is it applied? What is the nature of substrate? What are the conditions? What is the life-cycle of the material? These are only a few of the factors to consider. Once the packaging engineer has this information, they should contact a converter together with the label material manufacturer, such as Avery Dennison, for assistance in choosing the right label material for the application before getting started.
Benoît: I agree with Jos. It’s essentially
a combination of choosing the correct label material and the printing method that will be used to create the label. All of this will be influenced by the substrate’s nature, the application’s conditions, and so on.
The supply chain and volume will affect the printing technology, and the printing technology will impact the label material selection. There are therefore two main factors to consider here. The first factor concerns the label’s ability to adhere to and remain on the substrate. And the second, as previously said, is the printing of medical information that is crucial to the patient.
It is very important to make sure the label materials are compatible with the printing methods you choose; you can use either digital or conventional printing methods depending on your supply chain, the degree of flexibility required, the complexity level,
the volume, etc.
Thus, when it comes to packaging, you should consider the label material and printing technologies together instead of separately, and involve a label converter with the label material supplier, like Avery Dennison. That’s where AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader in the packaging industry.
Benoît
Jos
Jos
Benoît
There appear to be numerous parameters
to consider when it comes to a label (not to mention the whole packaging). Is it possible to pre select a label material for a specific application without conducting time-consuming and costly in-production tests?
There appear to be numerous parameters to consider when it comes to a label (not to mention the whole packaging). Is it possible to pre select a label material for a specific application without conducting time-consuming and costly in-production tests?
Jos: The typical method we’ve seen in the market is that the end-user or brand owner will collect all of the CTQs (as stated in the previous question), then select the test label material with the converter, and finally perform some testing. So, we created AD Procerta, a facility where a variety of label-specific tests can be performed with the guidance of an expert team to determine whether a label is suitable for a given application. Due to AD Procerta’s experience, your cycle time for introducing new material is reduced, and you’re assured of high-quality service because we’re working according to ISO 17025 standards.
Benoît: Essentially, we discovered that running labelling trials on manufacturing packaging lines can be difficult and costly (since production of the medicines must stop for the label the trial to take place). As you can imagine, it is difficult for packaging engineers to convince plant operations to allocate extra time for application trials within the plant.
In response to this challenge, we created laboratories that can mimic real life-cycles to speed up selection of label materials. Using this method, we can determine which label material has the greatest likelihood of success based upon effective tests in real-life scenarios that allow them to compare and contrast the options fairly. Therefore, to answer the question - yes, it is entirely possible to select the right material for the right application without spending a lot of time and money.
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
Jos: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
Benoît
Jos
There appear to be numerous parameters to consider when it comes to a label (not to mention the whole packaging). Is it possible to pre select a label material for a specific application without conducting time-consuming and costly in-production tests?
Jos: The typical method we’ve seen in the market is that the end-user or brand owner will collect all of the CTQs (as stated in the previous question), then select the test label material with the converter, and finally perform some testing. So, we created AD Procerta, a facility where a variety of label-specific tests can be performed with the guidance of an expert team to determine whether a label is suitable for a given application. Due to AD Procerta’s experience, your cycle time for introducing new material is reduced, and you’re assured of high-quality service because we’re working according to ISO 17025 standards.
Benoît: Essentially, we discovered that running labelling trials on manufacturing packaging lines can be difficult and costly (since production of the medicines must stop for the label the trial to take place). As you can imagine, it is difficult for packaging engineers to convince plant operations to allocate extra time for application trials within the plant.
In response to this challenge, we created laboratories that can mimic real life-cycles to speed up selection of label materials. Using this method, we can determine which label material has the greatest likelihood of success based upon effective tests in real-life scenarios that allow them to compare and contrast the options fairly. Therefore, to answer the question - yes, it is entirely possible to select the right material for the right application without spending a lot of time and money.
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
Jos: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
Jos: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
Jos
There appear to be numerous parameters to consider when it comes to a label (not to mention the whole packaging). Is it possible to pre select a label material for a specific application without conducting time-consuming and costly in-production tests?
Jos: The typical method we’ve seen in the market is that the end-user or brand owner will collect all of the CTQs (as stated in the previous question), then select the test label material with the converter, and finally perform some testing. So, we created AD Procerta, a facility where a variety of label-specific tests can be performed with the guidance of an expert team to determine whether a label is suitable for a given application. Due to AD Procerta’s experience, your cycle time for introducing new material is reduced, and you’re assured of high-quality service because we’re working according to ISO 17025 standards.
Benoît: Essentially, we discovered that running labelling trials on manufacturing packaging lines can be difficult and costly (since production of the medicines must stop for the label the trial to take place). As you can imagine, it is difficult for packaging engineers to convince plant operations to allocate extra time for application trials within the plant.
In response to this challenge, we created laboratories that can mimic real life-cycles to speed up selection of label materials. Using this method, we can determine which label material has the greatest likelihood of success based upon effective tests in real-life scenarios that allow them to compare and contrast the options fairly. Therefore, to answer the question - yes, it is entirely possible to select the right material for the right application without spending a lot of time and money.
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
Jos: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
What can AD Procerta clients expect from you?
Benoît: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
Jos: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
Benoît
Jos
: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
Benoît
: The label is often the last phase of the packaging development, but it is an essential component since it will contain all the information necessary for patient safety. When it comes to printing information on products like medication, any application defects or lack of readability must really be avoided at all costs - the labels have to
be highly robust. Putting it simply, you can’t use medication if its label doesn’t display all of the necessary information. But having said that, I believe people are gradually recognizing the importance of labels in packaging and are no longer putting them off until the last moment, which is a positive and essential shift.
: Physically, labels are a small component of a package, but they convey a great deal of information to its users. They contain crucial information such as usage and expiration dates, and each of these elements, as Benoît previously stated, are critical for a pharmaceutical product and hence deserves a great deal of time, thought, and attention.
Labels are viewed as only a small component of packaging by many people. What is your perspective on this?
Benoît
When a packaging engineer considers a labelling solution for a product’s packaging, where should they begin?
Jos
: If I were a packaging engineer, I’d start by gathering all of the CTQs (critical to quality) for a label. How is it applied? What is the nature of substrate? What are the conditions? What is the life-cycle of the material? These are only a few
of the factors to consider. Once the packaging engineer has this information, they should contact a converter together with the label material manufacturer, such as Avery Dennison, for assistance in choosing the right label material for the application before getting started.
: I agree with Jos. It’s essentially a combination of choosing the correct label material and the printing method that will be used to create the label. All of this will be influenced by the substrate’s nature, the application’s conditions, and so on. The supply chain and volume will affect the printing technology, and the printing technology will impact the label material selection. There are therefore two main factors to consider here. The first factor concerns the label’s ability to adhere to and remain on the substrate. And the second, as previously said, is the printing of medical information that
is crucial to the patient.
It is very important to make sure the label materials are compatible with the printing methods you choose; you can use either digital or conventional printing methods depending on your supply chain, the degree of flexibility required,
the complexity level, the volume, etc.
Thus, when it comes to packaging, you should consider the label material and printing technologies together instead
of separately, and involve a label converter with the label material supplier, like Avery Dennison. That’s where
AD Procerta comes in, a new laboratory and testing facility service which is part of Avery Dennison, a global leader
in the packaging industry.
Benoît
Jos
There appear to be numerous parameters to consider when it comes to a label (not to mention the whole packaging).
Is it possible to pre select a label material for a specific application without conducting time-consuming and costly
in-production tests?
: The typical method we’ve seen in the market is that the end-user or brand owner will collect all of the CTQs (as stated in the previous question), then select the test label material with the converter, and finally perform some testing. So, we created AD Procerta, a facility where a variety of label-specific tests can be performed with the guidance of an expert team to determine whether a label is suitable for a given application. Due to AD Procerta’s experience, your cycle time for introducing new material is reduced, and you’re assured of high-quality service because we’re working according to ISO 17025 standards.
: Essentially, we discovered that running labelling trials on manufacturing packaging lines can be difficult and costly (since production of the medicines must stop for the label the trial to take place). As you can imagine, it is difficult for packaging engineers to convince plant operations to allocate extra time for application trials within the plant.
In response to this challenge, we created laboratories that can mimic real life-cycles to speed up selection of label materials. Using this method, we can determine which label material has the greatest likelihood of success based upon effective tests in real-life scenarios that allow them to compare and contrast the options fairly. Therefore, to answer the question - yes, it is entirely possible to select the right material for the right application without spending a lot of time and money.
Benoît
Jos
AD Procerta works under the umbrella of Avery Dennison Corporation, a company where Stanton Avery produced the first pressure-sensitive label approximately 100 years ago. How do you build on this knowledge?
: Having developed labels and innovations for labeling applications for so many years has taught us a lot about the different types of adhesives available and how to test labels vigorously. The goal of testing labels isn’t merely to ensure they stick well and have strong adhesion; it’s also to understand how they perform in the application. As noted, with nearly a century of experience creating label materials, we have always tried to bring the application inside our R&D facilities to better understand how the label should perform. We can narrow down the selection of materials for certain applications based on this information. For example, we know how labels should survive on a syringe with a very small diameter and how they should be tested for low temperatures. To accomplish this, we have built equipment that performs precise application testing. The knowledge and expertise that Avery Dennison provides in these areas are undoubtedly beneficial, and we utilize it accordingly.
Jos
What can AD Procerta clients expect from you?
: Yes, the service has been piloted with a few big pharmaceutical companies (whose names we can’t disclose due to confidentiality) for the past two years, and we understood from the start that our plan was to offer it to the entire market in 2022. Having learned from these pilot customers, we’re now working with more than 5 large pharma companies and a few smaller ones as well.
: Our clients can expect to find an unbiased approach based upon facts and trustworthy relationships that will be kept confidential (as we typically work with non-disclosure agreements). Since we follow ISO 17025 guidelines, all test protocols that we set down with clients are done without bias, including making conclusions based on facts.
: Indeed, AD Procerta follows ISO 17025 guidelines, which means that all testing methods are evaluated on a regular basis and employees are continuously trained. Additionally, every piece of equipment is calibrated according to these standards. It is important to us that we operate independently in a transparent manner, and we have regular dialogs with our clients to let them know exactly what we test, how we test, and ensure that we agree on the Test Protocol before we start our work. The customer will even be notified if anything is discovered during the process that does not comply with what we originally stated. Thus, customers can expect thorough testing, comprehensive reporting, and independent analysis of the results.
Benoît
Jos
You’re just getting started with AD Procerta, so do you already have any pharmaceutical clients?
Benoît
Benoit Jourde
benoit.jourde@eu.averydennison.com
Benoit Jourde
benoit.jourde@eu.averydennison.com
download
our
brochure
